New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 20, 2014
07:16 EDTMDT, EWEdwards, Medtronic agree to global transcatheter valve litigation settlement
Edwards Lifesciences (EW) announced that the company has reached an agreement with Medtronic (MDT) to settle all outstanding patent litigation between the companies, including cases related to transcatheter heart valves. The agreement will result in the dismissal of all pending cases or appeals in courts and patent offices worldwide, and includes a provision that the parties will not litigate patent disputes with each other in the field of transcatheter valves for the eight-year duration of the agreement. Under the terms of a patent cross-license agreement that is part of the settlement, Medtronic will make a one-time payment to Edwards of $750M. Additionally, Medtronic will pay Edwards quarterly license royalty payments through April 2022. These payments will be based on a percentage of Medtronic CoreValve sales, subject to a minimum annual payment of $40M. Edwards will contribute $50M from the settlement to the Edwards Lifesciences Foundation to support efforts to improve patient care, raise disease awareness and educate clinicians, such as through its Every Heartbeat Matters philanthropic program.
News For EW;MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
07:58 EDTEWEdwards Lifesciences price target raised to $179 from $157 at Stifel
Subscribe for More Information
07:46 EDTEWEdwards Lifesciences price target raised to $178 from $160 at Canaccord
Subscribe for More Information
07:43 EDTEWEdwards Lifesciences price target raised to $185 from $155 at Leerink
Subscribe for More Information
07:23 EDTEWEdwards Lifesciences price target raised to $168 from $155 at JPMorgan
Subscribe for More Information
July 28, 2015
16:30 EDTEWEdwards Lifesciences sees Q3 EPS 92c-$1.00, consensus 98c
Sees Q3 revenue $580M-$620M, consensus $587.06M.
16:28 EDTEWEdwards Lifesciences raises FY15 EPS view to $4.30-44.40, consensus $4.28
Backs FY15 revenue view $2.3B-$2.5B, consensus $2.41B
16:26 EDTEWEdwards Lifesciences reports Q2 EPS $1.13 , consensus $1.05
Subscribe for More Information
15:21 EDTEWNotable companies reporting after market close
Subscribe for More Information
July 22, 2015
10:15 EDTMDTThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use